{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:33:24Z","timestamp":1774352004817,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of  China","doi-asserted-by":"crossref","award":["Grant No. 82072265"],"award-info":[{"award-number":["Grant No. 82072265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of  China","doi-asserted-by":"crossref","award":["Grant No. 82072265"],"award-info":[{"award-number":["Grant No. 82072265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of  China","doi-asserted-by":"crossref","award":["Grant No. 82072265"],"award-info":[{"award-number":["Grant No. 82072265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of  China","doi-asserted-by":"crossref","award":["Grant No. 82072265"],"award-info":[{"award-number":["Grant No. 82072265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Project of Guangzhou","award":["Grant No. 2023A03J0792 and 2024A03J0880"],"award-info":[{"award-number":["Grant No. 2023A03J0792 and 2024A03J0880"]}]},{"name":"the Science and Technology Project of Guangzhou","award":["Grant No. 2023A03J0792 and 2024A03J0880"],"award-info":[{"award-number":["Grant No. 2023A03J0792 and 2024A03J0880"]}]},{"name":"the Science and Technology Project of Guangzhou","award":["Grant No. 2023A03J0792 and 2024A03J0880"],"award-info":[{"award-number":["Grant No. 2023A03J0792 and 2024A03J0880"]}]},{"name":"the Science and Technology Project of Guangzhou","award":["Grant No. 2023A03J0792 and 2024A03J0880"],"award-info":[{"award-number":["Grant No. 2023A03J0792 and 2024A03J0880"]}]},{"name":"the National Key Research and  Development Program of China","award":["Grant No.2022YFC2304800"],"award-info":[{"award-number":["Grant No.2022YFC2304800"]}]},{"name":"the National Key Research and  Development Program of China","award":["Grant No.2022YFC2304800"],"award-info":[{"award-number":["Grant No.2022YFC2304800"]}]},{"name":"the National Key Research and  Development Program of China","award":["Grant No.2022YFC2304800"],"award-info":[{"award-number":["Grant No.2022YFC2304800"]}]},{"name":"the National Key Research and  Development Program of China","award":["Grant No.2022YFC2304800"],"award-info":[{"award-number":["Grant No.2022YFC2304800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02794-8","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:01:31Z","timestamp":1747670491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Yaozu","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baolin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuantao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2794_CR1","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.lanepe.2023.100738","volume":"34","author":"D G\u00f6kengin","year":"2023","unstructured":"G\u00f6kengin D, Noori T, Alemany A, et al. Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe. Lancet Reg Health Eur. 2023;34:100738.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"2794_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","volume":"73","author":"ML Yeh","year":"2020","unstructured":"Yeh ML, Huang CF, Huang CI, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection. J Hepatol. 2020;73(1):62\u201371.","journal-title":"J Hepatol"},{"key":"2794_CR3","doi-asserted-by":"publisher","first-page":"726419","DOI":"10.3389\/fimmu.2021.726419","volume":"12","author":"ST Gobran","year":"2021","unstructured":"Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV\/HIV Coinfection. Front Immunol. 2021;12:726419.","journal-title":"Front Immunol"},{"issue":"12","key":"2794_CR4","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1016\/S1473-3099(20)30765-9","volume":"21","author":"U Arora","year":"2021","unstructured":"Arora U, Garg P, Agarwal S, et al. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis. Lancet Infect Dis. 2021;21(12):e399\u2013406.","journal-title":"Lancet Infect Dis"},{"issue":"38","key":"2794_CR5","doi-asserted-by":"publisher","first-page":"35435","DOI":"10.1074\/jbc.M103020200","volume":"276","author":"M G\u00f3mez-gonzalo","year":"2001","unstructured":"G\u00f3mez-gonzalo M, Carretero M, Rullas J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB\/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem. 2001;276(38):35435\u201343.","journal-title":"J Biol Chem"},{"issue":"2","key":"2794_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/cells10020410","volume":"10","author":"A Gruevska","year":"2021","unstructured":"Gruevska A, Moragrega AB, Cossarizza A, et al. Apoptosis of hepatocytes: relevance for hiv-infected patients under treatment. Cells. 2021;10(2):410.","journal-title":"Cells"},{"issue":"3","key":"2794_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.31839","volume":"74","author":"HN Kim","year":"2021","unstructured":"Kim HN, Newcomb CW, Carbonari DM, et al. Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America. Hepatology (Baltimore, MD). 2021;74(3):1190\u2013202.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"2794_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1021\/acs.joc.0c02318","volume":"86","author":"A Council","year":"2021","unstructured":"Council A. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. J Org Chem. 2021;86(1):693\u2013708.","journal-title":"J Org Chem"},{"key":"2794_CR9","unstructured":"SOCIETY EAC. EACS Guidelines, Version 12.0, October 2023. 2021."},{"issue":"4","key":"2794_CR10","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","volume":"10","author":"J Nie","year":"2021","unstructured":"Nie J, Sun F, He X, et al. Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China. Infect Dis Ther. 2021;10(4):2611\u201323.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"2794_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/v11080705","volume":"11","author":"J Pu","year":"2019","unstructured":"Pu J, Wang Q, Xu W, et al. Development of protein- and peptide-based HIV entry inhibitors targeting gp120 or gp41. Viruses. 2019;11(8):705.","journal-title":"Viruses"},{"issue":"3","key":"2794_CR12","doi-asserted-by":"publisher","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","volume":"7","author":"H Chong","year":"2012","unstructured":"Chong H, Yao X, Zhang C, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One. 2012;7(3):e32599.","journal-title":"PLoS One"},{"issue":"20","key":"2794_CR13","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.3390\/molecules29204951","volume":"29","author":"NM Helmy","year":"2024","unstructured":"Helmy NM, Parang K. The role of peptides in combatting HIV infection: applications and insights. Molecules. 2024;29(20):4951.","journal-title":"Molecules"},{"issue":"2","key":"2794_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.01534-07","volume":"82","author":"K Shimura","year":"2008","unstructured":"Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137). J Virol. 2008;82(2):764\u201374.","journal-title":"J Virol"},{"issue":"12","key":"2794_CR15","doi-asserted-by":"publisher","first-page":"e0145772","DOI":"10.1371\/journal.pone.0145772","volume":"10","author":"SY Rhee","year":"2015","unstructured":"Rhee SY, Jordan MR, Raizes E, et al. HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing. PLoS One. 2015;10(12):e0145772.","journal-title":"PLoS One"},{"issue":"5","key":"2794_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2794_CR17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1097\/QAD.0b013e328216f15b","volume":"21","author":"CA Fux","year":"2007","unstructured":"Fux CA, Christen A, Zgraggen S, et al. Effect of tenofovir on renal glomerular and tubular function. AIDS (London, England). 2007;21(11):1483\u20135.","journal-title":"AIDS (London, England)"},{"key":"2794_CR18","unstructured":"World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens: policy brief. Geneva, Switzerland: WHO; 2019. WHO\/CDS\/HIV\/19.15. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/325892. Accessed 15 July 2024."},{"key":"2794_CR19","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2024. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 30 Jan 2025."},{"issue":"3","key":"2794_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355.","journal-title":"Lancet Infect Dis"},{"key":"2794_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-021-01653-6","volume":"18","author":"Y Lan","year":"2021","unstructured":"Lan Y, Li L, He X, et al. Transmitted drug resistance and transmission clusters among HIV-1 treatment-na\u00efve patients in Guangdong, China: a cross-sectional study. Virol J. 2021;18:1\u20139.","journal-title":"Virol J"},{"key":"2794_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","volume":"9","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara B, Lessells RJ, Rhee SY, et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000\u20132016: a pooled sequence analysis. EClinicalMedicine. 2019;9:26\u201334.","journal-title":"EClinicalMedicine"},{"issue":"17","key":"2794_CR23","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3390\/molecules26175305","volume":"26","author":"RF Cunha","year":"2021","unstructured":"Cunha RF, Sim\u00f5es S, Carvalheiro M, et al. Novel antiretroviral therapeutic strategies for HIV. Molecules. 2021;26(17):5305.","journal-title":"Molecules"},{"issue":"3","key":"2794_CR24","doi-asserted-by":"publisher","first-page":"135965352311747","DOI":"10.1177\/13596535231174774","volume":"28","author":"JA Aberg","year":"2023","unstructured":"Aberg JA, Mills A, Moreno S, et al. The evolution of clinical study design in heavily treatment-experienced persons with HIV: a critical review. Antivir Ther. 2023;28(3):13596535231174774.","journal-title":"Antivir Ther"},{"issue":"15","key":"2794_CR25","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","volume":"31","author":"KP Singh","year":"2017","unstructured":"Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31(15):2035\u201352.","journal-title":"AIDS"},{"key":"2794_CR26","doi-asserted-by":"publisher","first-page":"105348","DOI":"10.1016\/j.antiviral.2022.105348","volume":"203","author":"T Liu","year":"2022","unstructured":"Liu T, Sun Q, Gu J, et al. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Res. 2022;203:105348.","journal-title":"Antiviral Res"},{"issue":"24","key":"2794_CR27","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","volume":"133","author":"B Su","year":"2020","unstructured":"Su B, Yao C, Zhao QX, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919\u201327.","journal-title":"Chin Med J (Engl)"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02794-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:01:34Z","timestamp":1747670494000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02794-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02794-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Guangzhou Eighth People\u2019s Hospital (approved number: 202033166) and was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of good clinical practice. We hereby declare that informed consent was obtained from the patient for the publication of all images, clinical data, and other data included in this manuscript. The patient has agreed and fully understands the nature of our study, as well as the use and publication of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}